KALA BIO (KALA) Projected to Post Earnings on Thursday

KALA BIO (NASDAQ:KALA) is expected to be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($2.47) per share for the quarter.

KALA BIO Stock Performance

NASDAQ KALA opened at $6.70 on Wednesday. The company has a current ratio of 2.15, a quick ratio of 2.15 and a debt-to-equity ratio of 3.18. The company has a fifty day simple moving average of $7.75 and a 200 day simple moving average of $6.81. KALA BIO has a 12-month low of $4.21 and a 12-month high of $11.20. The company has a market cap of $40.81 million, a P/E ratio of -0.54 and a beta of -2.19.

Insider Activity at KALA BIO

In other news, major shareholder Bros. Advisors Lp Baker purchased 310,559 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average cost of $6.44 per share, for a total transaction of $1,999,999.96. Following the completion of the acquisition, the insider now owns 1,083,398 shares in the company, valued at $6,977,083.12. This trade represents a 40.18 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Mark T. Iwicki sold 5,779 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.63, for a total transaction of $44,093.77. Following the completion of the sale, the chief executive officer now directly owns 280,076 shares of the company’s stock, valued at $2,136,979.88. The trade was a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,506 shares of company stock valued at $72,531 over the last 90 days. Insiders own 8.32% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of KALA BIO in a report on Thursday, February 13th.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.